Local websites
Businesses
Other websites
General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

More information

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

More information

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

More information

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

 

Latest news

17-Jun-2013
Three Scientists to Receive Prestigious Novartis Prizes for Immunology at 15th International Congress of Immunology

16-Jun-2013
Novartis drug Jakavi® improved overall survival of myelofibrosis patients and impacted an underlying mechanism of disease

10-Jun-2013
Switching to Novartis drug Gilenya from standard interferon shown to improve long-term outcomes for patients with multiple sclerosis

Investor Insights logo

Investor Insights is a newsletter in which you will find:

  • Interesting feedback we have recently received from investors
  • Investor FAQs
  • Updates on specific Novartis initiatives and happenings

Stay up-to-date

View Novartis images on Flickr

Subscribe to the Novartis YouTube channel

English newsfeed

German newsfeed

French newsfeed

Top links
Top downloads
Stock chart

Stock performance

Annual report cover

Annual Report and Form 20-F 2012 >